• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Julia H. Hayes, MD


  • Hayes JH, Nakabayashi M, Kantoff PW.Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.Cancer. 2013 Nov 15;119(22):4053.
  • Hayes JH, Barry MJ, McMahon PM.Observation versus initial treatment for prostate cancer.Ann Intern Med. 2013 Oct 15;159(8):574.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM.Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.Ann Intern Med. 2013 Jun 18;158(12):853-60.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.BJU Int. 2012 Aug 29.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.JAMA. 2010 Dec 1;304(21):2373-80.
  • Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV.Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.BJU Int. 2010 Oct;106(7):979-85.
  • Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.Cancer. 2010 Apr 15;116(8):1887-92.